Health-related quality of life under six months' treatment of migraine--an open clinic-based longitudinal study.
Health-related quality of life (HQL) assessment in the clinical setting have distinguished subjective perceptions (e.g., well-being), signs/symptoms of the disease and functional capacity as three major components. The impact of short-term treatment for migraine attacks on these variables was evaluated in an open prospective 6-month study at the Gothenburg Migraine Clinic. Socio-economic factors, subjective symptoms, and general well-being/quality of life were evaluated by self-administered questionnaires in 99 patients with migraine with or without aura in accordance with the classification of the International Headache Society. Short-term treatment comprising conventional therapy or subcutaneous sumatriptan reduced number of days per month with migraine and absenteeism from work, migraine-associated symptoms, but did not significantly improve general well-being between attacks. Future assessment of the patients' HQL in accordance with this approach would enable us to consider all the advantages and disadvantages of current therapies of particular interest in the field of migraine.
Dahlöf
C G
CG
Gothenburg Migraine Clinic, Göteborg, Sweden.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008499:Medical Records; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D011433:Propranolol / Q000627:therapeutic use; D011446:Prospective Studies; D011788:Quality of Life; D012959:Socioeconomic Factors; D018170:Sumatriptan / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D014662:Vasoconstrictor Agents; D018170:Sumatriptan; D011433:Propranolol